Mumbai, Sept. 6 -- Lupin announced that the U.S. FDA has conducted a product-specific Pre-Approval Inspection (PAI) at the Company's Chhatrapati Sambhajinagar (Aurangabad) manufacturing facility from 01 September to 05 September 2025. The inspection closed with two observations.

Published by HT Digital Content Services with permission from Capital Market....